Trial · NCT02228590
Results by group55
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 55
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| The Percentage of Patients With Resolution of an 'OFF' Episode to an 'ON' State Following Administration of APL-130277 | APL-130277 | Overall | 78.9 | percentage of participants | |
| The Percentage of Patients With Resolution of an 'OFF' Episode to an 'ON' State Following Administration of APL-130277 | APL-130277 | 15 minutes post-dose | 31.6 | percentage of participants | |
| The Percentage of Patients With Resolution of an 'OFF' Episode to an 'ON' State Following Administration of APL-130277 | APL-130277 | 30 minutes post-dose | 78.9 | percentage of participants | |
| The Percentage of Patients With Resolution of an 'OFF' Episode to an 'ON' State Following Administration of APL-130277 | APL-130277 | 45 minutes post-dose | 68.4 | percentage of participants | |
| The Percentage of Patients With Resolution of an 'OFF' Episode to an 'ON' State Following Administration of APL-130277 | APL-130277 | 60 minutes post-dose | 68.4 | percentage of participants | |
| The Percentage of Patients With Resolution of an 'OFF' Episode to an 'ON' State Following Administration of APL-130277 | APL-130277 | 90 minutes post-dose | 47.4 | percentage of participants | |
| Time to 'ON' State From Time of Dosing of APL-130277 | APL-130277 | 24.0 | Standard Deviation 7.61 | minutes | |
| Duration of 'ON' Response From Time of Dosing of APL-130277 | APL-130277 | 50.0 | Standard Deviation 19.36 | minutes | |
| Percentage of Patients Who Completed the Trial and Experienced an 'ON' Episode | APL-130277 | 78.9 | percentage of participants | ||
| Pharmacokinetic (PK) Evaluation: Maximum Observed Plasma Concentration (Cmax) | APL-130277 | 10 mg APL-130277 Dose 1 Day 1 | 2.01 | Standard Deviation 0.914 | ng/mL |
| Pharmacokinetic (PK) Evaluation: Maximum Observed Plasma Concentration (Cmax) | APL-130277 | 15 mg APL-130277 Dose 2 Day 1 | 2.52 | Standard Deviation 1.04 | ng/mL |
| Pharmacokinetic (PK) Evaluation: Maximum Observed Plasma Concentration (Cmax) | APL-130277 | 10 mg APL-130277 Dose 1 Day 2 | 4.18 | Standard Deviation NA | ng/mL |
| Pharmacokinetic (PK) Evaluation: Maximum Observed Plasma Concentration (Cmax) | APL-130277 | 20 mg APL-130277 Dose 1 Day 2 | 3.82 | Standard Deviation 1.81 | ng/mL |
| Pharmacokinetic (PK) Evaluation: Maximum Observed Plasma Concentration (Cmax) | APL-130277 | 25 mg APL-130277 Dose 2 Day 2 | 4.84 | Standard Deviation NA | ng/mL |
| Pharmacokinetic (PK) Evaluation: Maximum Observed Plasma Concentration (Cmax) | APL-130277 | 20 mg APL-130277 Dose 1 Day 3 | 2.82 | Standard Deviation 1.38 | ng/mL |
| Pharmacokinetic (PK) Evaluation: Maximum Observed Plasma Concentration (Cmax) | APL-130277 | 25 mg APL-130277 Dose 1 Day 3 | 12.3 | Standard Deviation NA | ng/mL |
| Pharmacokinetic (PK) Evaluation: Maximum Observed Plasma Concentration (Cmax) | APL-130277 | 30 mg APL-130277 Dose 1 Day 3 | 4.22 | Standard Deviation NA | ng/mL |
| Pharmacokinetic (PK) Evaluation: Maximum Observed Plasma Concentration (Cmax) | APL-130277 | 25 mg APL-130277 Dose 2 Day 3 | 4.84 | Standard Deviation 2.99 | ng/mL |
| PK Evaluation: Time of Maximum Observed Plasma Concentration (Tmax) | APL-130277 | 10 mg APL-130277 Dose 1 Day 1 | 60.0 | Full Range 45.0 to 90.0 | minutes |
| PK Evaluation: Time of Maximum Observed Plasma Concentration (Tmax) | APL-130277 | 15 mg APL-130277 Dose 2 Day 1 | 35.0 | Full Range 24.0 to 90.0 | minutes |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02228590/results